Modality
Radioligand
MOA
BCL-2i
Target
PSMA
Pathway
Notch
Wet AMDPancreatic Ca
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
~Jun 2020
→ ~Sep 2021
Phase 2
~Dec 2021
→ ~Mar 2023
Phase 3
~Jun 2023
→ ~Sep 2024
NDA/BLA
Dec 2024
→ May 2029
NDA/BLACurrent
NCT05893585
1,895 pts·Wet AMD
2024-12→2029-05·Not yet recruiting
1,895 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-05-123.1y awayPh3 Readout· Wet AMD
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2029-05-12 · 3.1y away
Wet AMD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05893585 | NDA/BLA | Wet AMD | Not yet recr... | 1895 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| BII-1564 | Biogen | Phase 2 | PSMA |